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The termination of a specifically induced unresponsive state can be achieved
by immunizing tolerant animals with antigens which cross-react with the toler-
ated antigen. For example, rabbits made tolerant to bovine serumalbumin (BSA)'
by the injection of large amounts ofBSA during the perinatal period are refrac-
tive to immunogenic challenges of aqueous preparations of BSA when tested at
3 mo of age. However, when similarly treated animals are challenged with aque-
ous preparations of certain cross-reacting albumins such as human serum albu-
min (HSA), they produced circulating antibody that reacts with both the cross-
reacting albumin and BSA although none of the antibody is specific for BSA (1).
Furthermore, the antibody response to BSA is quantitatively and qualitatively
indistinguishable from the antibody response to BSA elicited by the injection of
HSA into normal rabbits. These data suggest that at 3 mo of age, rabbits made
tolerant at birth possess a normal anti-BSA antibody-forming potential, that is,
a normal complement of B cells specific for the tolerated antigen.
Considered within the framework of cellular cooperation necessary for anti-
body formation to a number of antigens (2), a cellular interpretation for this
phenomenon can be formulated whereby tolerance to BSA at the time of testing
(3 mo) is maintained by the functional absence of the BSA-specific carrier
recognition mechanism (T cells) in spite of the presence of B cells capable of
responding to the antigen. The response manifested by the injection of HSA
could then be viewed as the antigen-mediated cooperation betweenBSA-specific
B cells recognizing on HSA those determinants which cross-react with BSA, and
HSA-specific T cells recognizing on HSA determinants noncross-reactive with
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BSA. The temporal aspects of such a model are compatible with the kinetics
which characterize the spontaneous loss oftolerance in Tcells and B cells in mice
(3).
Predictably tolerance could be terminated at a time when unresponsiveness to
B:SA is restricted to specific T cells by using a complex composed ofthe tolerogen
(BSA) conjugated to a carrier molecule which itself is immunologically recogniz-
able. Inasmuch as a gross alteration of the BSA molecule can itself lead to
specific termination (4), the system chosen to test this prediction for this study
was antibody which was coupled to the antigen by immunological complexing in
order to minimize alteration ofthe antigen (BSA). The results to be reported will
demonstrate that, in accord with the predictions, such complexes can terminate
tolerance notonly in a state ofexperimentally induced unresponsiveness but also
in a state of natural unresponsiveness.
Materials and Methods
Antigens.
￿
Commercial preparations of BSA and HSA were obtained from Armour Pharmaceuti-
cal Co., Chicago, Ill., lot F 71703, and from E. R. Squibb & Sons, New York, lot 591R (prepared from
material supplied through the courtesy of the American Red Cross), respectively. Rabbit thyro-
globulin (RTg) and bovine thyroglobulin (BTg) were isolated and purified using a modification (5) of
the technique described by Edelhoch (6) . Rabbit thyroids were obtained from the trachea of New
Zealand White rabbits obtained fresh (unfrozen) from Pel-Freez Biologicals, Inc., Rogers, Ark., and
bovine thyroids were obtained from a local slaughterhouse.
Animals.
￿
All rabbits used in these studies were of the New Zealand White strain. Hartley strain
guinea pigs weighing approximately 400 g were used for the production of antisera to HSA and to
BTg.
Induction of Immunological Tolerance to BSA.
￿
Rabbits were made tolerant to BSA by the
subcutaneous injection of 100 mg BSA during the first 24 h of life followed by two injections of 200 mg
each before the 5th day of life. This procedure renders all rabbits unresponsive to an intravenous
challenge of 20 mg BSA for as long as 6 mo (7) .
Antibody Assays
HEMOLYTIC PLAQUE ASSAY. Lymphoid cell suspensions were prepared from the popliteal lymph
nodes and spleens of immunized rabbits. Recovered cells from single spleens (1-5 x 108 cells) or
lymph nodes (4-9 x 108 cells) were suspended in balanced salt solution (BSS) (8).
Protein, either BSA or normal guinea pig gamma globulin (GPGG), was conjugated to washed goat
erythrocytes using a water-soluble carbodiimide [1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
HCI1 according to the method of Golub et al. (9) . The antigen-coupled erythrocytes were washed
three times in phosphate-buffered saline and then diluted 1:15 in BSS for use in the hemolytic plaque
assay. The assay used was the Jerne plaque assay (10) as modified by Mishell and Dutton (8) .
INHIBITION OF PLAQUE-FORMING CELLS (PFC) WITH SOLUBLE ANTIGENS .
￿
The amount of BSA conjugated
to the erythrocytes was estimated and a 1,000-fold molar excess of either soluble BSA or HSA was
added to the agarose-cell mixture for plating.
PRECIPITIN ANALYSIS . Measurement of antibodies for injection was made using a quantitative
precipitin technique employing "5I-labeled antigen (11).
FREER TEST FOR PRECIPITATING ANTIBODY. The presence of precipitating antibodies to RTg was
determined using the one dimensional diffusion analysis described by Preer (12).
HEMAGGLUTINATION ASSAY .
￿
Hemagglutination (13) was performed using a 2.5% suspension of
tannic acid-treated sheep erythrocytes sensitized with 0.5 mg RTg/ml. Before testing, sera were
absorbed with an equal volume of sheep erythrocytes and heated at 56°C for 20 min .
Preparation ofAntibodies.
￿
Guinea pig anti-HSA was prepared by giving three injections each of
0.2 mg HSA in 1 ml of complete Freund's adjuvant which contained 0.2 mg Mycobacterium
tuberculosis distributed in four subcutaneous sites. The level of precipitating antibody in individual
sera was estimated using varying concentrations of HSA or BSA in the Ouchterlony double-diffusion314
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analysis (14) . High titer antisera were pooled and quantitated. This pooled antiserum contained 6.5
mg anti-HSA antibody/ml of which 1 ml bound 0.7 mg BSA.
Rabbits were immunized with HSA in complete Freund's adjuvant using aseries of six injections
over a 4-mo period. Each 1-ml injection contained 10 mg HSA and 3.4 mg mycobacteria and was
distributed between foot pads and subcutaneous sites . Antisera showing a strong reaction in the
Ouchterlony double-diffusion analysis were grouped into two pools. Pool I contained 14.2 mg
precipitating anti-HSA/ml of which 1 ml bound 0.3 mg BSA. Pool II had 6.8 mg precipitating
anti-HSA antibody/ml of which 1 ml bound 0.4 mg BSA.
Guinea pig anti-BTg was prepared by injection of BTg incorporated into complete Freund's
adjuvant containing 0.2 mg mycobacteria/ml. On days 0 and 14, 5 mg BTg in 1 ml complete Freund's
adjuvant was divided between the hind foot pads and two subcutaneous sites. The third injection
(day 21) was made in four subcutaneous sites. The animals were bled on days 42, 49, and 56 and the
resulting sera were grouped in twopools. Pool I contained 1 .1 mg precipitating anti-RTg/ml. Pool II
contained 0.5 mg precipitating anti-RTg/ml. Theantibody to antigen ratio of these antisera wasone.
Preparation of Complexes for Injection.
￿
All antigen-antibody complexes prepared for injection
were precipitated at the optimal proportions of antibody and cross-reacting antigen. The antigen-
antibody mixtures were incubated at 37°C for 30 min andthen at 4°C for at least 24 h. The resulting
precipitates were centrifuged and washed three times in cold saline. The washed precipitates were
resuspended in cold saline andthen incorporated into incomplete Freund's adjuvant for injection.
For both the serum albumin and thyroglobulin experiments, control groups were challenged with
GPGG in amounts equivalent to the amounts of guinea pig antibody received by the experimental
groups as calculated from the known combining ratios of the antigens with their antibodies. Other
control groups received injections of antigen alone in the same amounts used in complex form. All
challenge antigens or complexes were incorporated into Freund's adjuvant and injected in equal vol-
umes in the twohind foot pads.
Complexes of BSAwith guinea pig anti-HSA were prepared as described above so that each animal
received 36 ug BSA for the first challenge injection (day 0) and 179 peg BSA for the second (day 7) .
Complexes of BSA with rabbit anti-HSA were also prepared so that each animal received 36 kg BSA
and 179 lAg BSA in complex form for the first and second challenge injections, respectively.
Animals challenged with RTg complexed to guinea pig anti-BTg received three injections of 400,
800, and 1,200 jag RTg in complex form on days 0, 7, and 15, respectively. In another experiment,
rabbits received 266 and 800 Fig RTg in complex form on days 0 and 7, respectively.
Histology.
￿
Thyroid tissue was taken when the rabbits were sacrificed. The tissue was fixed in
Bouin's solution, embedded in paraffin, and sections cut through the long axis. The sections were
mounted and stained with hematoxylin and eosin.
The grading of thyroiditis was determined by the degree of cellular infiltration . The lesions were
graded + if at least five foci (the size of one follicle or more) of infiltrating cells were present in the
longitudinal section of one lobe. Lesions were graded ++ if 10-20 foci were present, each of which
occupied the area of several follicles. Lesions were graded +++ if either numerous foci were present
in each section, each of which occupied areas the size of anumber of follicles or the entire lobe was
involved with a more diffuse infiltration .
Results
Termination of Tolerance to BSA using Heterologous Antibody-Antigen
Complexes. Rabbits were made unresponsive to BSA by injection of BSA at
birth. At 3 mo of age, the tolerant rabbits were divided into three groups. Group
A was challenged with two injections of complexes of guinea pig anti-HSA plus
BSA which had been precipitated at equivalence. Groups B and C were
challenged with either BSA or GPGG, respectively. 8 days after the last
challenge, all rabbits were sacrificed and their popliteal lymph nodes and spleen
were assayed for PFC to BSA. The results shown in Table I indicate the extent of
the response of such treated animals as expressed by the number of indirect
anti-BSA PFC per 108 popliteal lymph node cells. No direct PFC were detected.
It can be seen that BSA in complex with guinea pig anti-HSA (group A)G. S . HABICHT, J. M. CHILLER, AND W. O. WEIGLE
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TABLE I
Termination of Immunological Unresponsiveness to BSA using
Immune Complexes Made with Heterologous Antibody
Inhibition of
* LN, lymph node.
$ All groups challenged with GPGG made aPFCresponse to GPGG in the
draining lymph node.
terminated the tolerant state while BSA alone (group B) did not. Furthermore,
100% of the BSA-specific PFC in the animals challenged with complexed BSA
were inhibited with soluble BSA but only 14% were inhibited by soluble HSA.
Thus, the specificity of the PFC response was directed to the previously tolerated
antigen. The weaker PFC response obtained in the assays of the splenic PFC
(data not shown) led nevertheless to conclusions similar to those made using
lymph node cells. Finally, draining popliteal lymph nodes from all animals
injected with GPGG alone or in complex (groups C and A, respectively) made a
PFC response to GPGG.
Termination of Tolerance to BSA using Homologous Antibody-Antigen
Complexes. 3-mo old BSA tolerant rabbits were challenged with two injections
of complexes of rabbit anti-HSA plus BSA which had been precipitated at
equivalence. The results in terms of numbers of PFC per 106 popliteal lymph
node cells are shown in Table 11. Rabbits challenged with the homologous
TABLE II
Termination of Immunological Unresponsiveness to BSA using
Immune Complexes Made with Homologous Antibody
Inhibition of
* LN, lymph node .
$Groups A and B received exactly the same experimental treatment but
are reported separately because of the bimodal distribution of the
results .
Group Challenge
No. of
animals
Indirect PFC/108
LN*cells (range)
PFC
BSA
by:
HSA
A Rabbit anti-HSA 5 130(74-245) 100 4
+ BSA$
B Rabbit anti-HSA 5 4(2-7) - -
+ BSA$
C BSA 5 9(0-31) - -
Group Challenge
No. of
animals
Indirect PFC/108
LN* cells (range)
PFC
BSA
by:
HSA
A GP anti-HSA$ 8 296(71-609) 100 14
+ BSA
B BSA S 6(0-31) - -
C GPGG$ 5 0 - -316
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antibody-antigen complex fell into two groups . One-half of the animals (group A)
showed some termination of unresponsiveness to BSA (71-275 PFC/106 lymph
node cells) while the others (group B) remained tolerant (2-7 PFC/10 6 lymph
node cells) . BSA alone did not terminate the tolerant state (group C).
Termination of Natural Unresponsiveness to RTg using Heterologous Anti-
body-Antigen Complexes. Normal rabbits, 3 mo of age, were divided into three
groups. Group A was challenged with three injections of complexes made of
guinea pig anti-BTg plus RTg mixed at equivalence. This group showed a
termination of the natural tolerant state to RTg as shown by the appearance of
hemagglutinating antibody in 9 of 10 animals and precipitating anti-RTg in 6 of
10, as well as the development of inflammatory lesions of the thyroid in 6 of 10
(Table III) . The groups challenged with RTg (group B) or GPGG (group C) alone
did not make an immune response to the RTg.
Discussion
Both experimentally induced and naturally acquired states of immunological
unresponsiveness (tolerance) can be terminated in rabbits injected with com-
plexes composed of heterologous cross-reacting antibody and the tolerated
antigen. In this manner, tolerance to BSA experimentally induced by the
injection of 500 mg BSA into neonatal rabbits was terminated when complexes
composed of guinea pig anti-HSA plus BSA were injected into the rabbits at 3 mo
of age. Similarly, it has been demonstrated that rabbits tolerant to GPGG lost
their experimentally induced unresponsive state when challenged with GPGG as
specific antibody complexed to ovalbumin or BSA (W. O. Weigle, unpublished
observation) . Analogous to these situations in which an induced unresponsive
state was abrogated, natural tolerance to a self-antigen, namely RTg, was
terminated by challengingwith complexes composed of guinea pig anti-BTg plus
RTg. This loss of self-tolerance was manifested by both the formation of humoral
antibody specific to RTg as well as by the histological demonstration of an
inflammatory, cellular infiltration of the thyroid.
TABLE III
Termination of NaturalImmunological Unresponsiveness to RTg
using Immune Complexes Made with Heterologous Antibody*
*These results represent data pooled from two different experiments. No
differences were observed between the two experimental sets although
one set received three injections of RTg totalling2,400 IxgRTgwhile the
other set received two injections of RTg totalling 1,066 kg RTg (see
Materials and Methods).
Group Challenge
No. of
animals
Anti-RTg
Hemagglu- ppt
Thyroid
lesions tination
(preer test) (range)
A GP anti-BTg 10 9/10 (16-5, 120) 6/10 6/10
+RTg
B RTg 11 2/11(16) 0/11 0/11
C GPGG 6 0/6 0/6 0/6G. S. HABICHT, J. M. CHILLER, AND W. O. WEIGLE
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The interpretation of these data must be considered within the context of those
cellular events which have been shown to delineate the state of tolerance to
serum protein antigens. For example, it has been shown that in mice tolerance
induced to human gamma globulin (HGG) is a function of the immunological
state of both the T and B cells (15) . However, tolerance restricted to specific T
cells is sufficient to maintain an apparent state of unresponsiveness in the intact
animal. This situation is observed in tolerant mice beginning some 2 mo after the
administration of tolerogen, that is, after B-cell tolerance has waned (3). Thus, it
could be assumed that BSA tolerant rabbits at 3 mo of age similarly have a
normal anti-BSA antibody-forming potential but lack the T-cell helper capacity
for recognizing BSA. This putative cellular status is in accord with data recently
reported by Benjamin (16) in which he was able to terminate tolerance to BSA in
rabbits by injecting normal thymocytes plus antigen at 3 mo of age. In that light,
termination of tolerance using cross-reacting antigens (17), altered antigen (4), or
heterologous antibody-antigen complexes can be seen as occurring in a cellular
state where tolerance is maintained by unresponsiveness at the level of specific T
cells in spite of the presence of a normal complement of B cells with the potential
to produce antibody specific for the tolerated antigen. In the case of the observed
termination of tolerance by BSA complexed to guinea pig anti-HSA, it might
thus be postulated that the unresponsive state was bypassed by using the T-cell
helper activity specific for determinants on GPGG in order to provide the B-T
cell collaboration necessary for the production of anti-BSA. Guinea pig anti-HSA
was chosen so that within the antigen-antibody complex, antigenic determinants
specific for BSA would remain exposed and thus be free to interact with the
BSA-specific B cells. In accord with this hypothetical mechanism, it would be
further predicted that the homologous immunoglobulin in complexes made of
rabbit anti-HSA plus BSA should not serve as an appropriate carrier inasmuch
as no helper T cells should be capable of recognizing naturally occurring
self-components. However, although rabbit anti-HSA plus BSA did not regularly
terminate tolerance, one half of the animals tested were shown to displaypositive
responses to the previously tolerated antigen. PFC responses in the half of the
animals which did show termination using homologous antibody-antigen com-
plexes were significantly (0 .025 < P < 0.05) lower (130 PFC/106 lymph node
cells) than those achieved using heterologous antibody-antigen complexes (296
PFC/106 lymphnode cells) . No termination was achieved in the remaininghalf of
the animals. That some animals did show termination of tolerance while others
did not may reflect immunoglobulin allotypic differences between the complexed
antibody and the challenged individual. Retrospective analysis of the allotypesof
the sera involved was not able to resolve this point.
In the case of natural tolerance to the rabbits' own thyroglobulin, low
circulating levels of thyroglobulin (10 ng/ml) although likely insufficient to
produce unresponsiveness in B cells should be capable of producing unrespon-
siveness in T cells (18) so that the natural tolerant state in this case would be
maintained at the T-cell level only. This situation would be analogous to that
which is obtained in mice injected with low doses of the tolerogen HGG (3). Very
low doses of tolerogen (0.1 mg) produced unresponsiveness at the T-cell level
only. Normal human and murine lymphoid tissues are known to contain B cells318
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with receptors which recognize their own thyroglobulins (19, 20). Thus, the useof
heterologous antibody complexed to RTg which bypassed the requirement for
helper T cells specific to GPGG was able to terminate the tolerant state as
manifested by circulating antibody and thyroiditis. Although it is possible to
terminate the natural tolerant state to self-antigens which occur in low
concentrations in the circulation, such as thyroglobulin, termination of tolerance
to antigens occurring in high concentrations, such as serum albumin, would not
be expected to occur.
Termination of the tolerant state which is being maintained at the T-cell level
only is achieved not only by bypassingthe specificity ofthe T cell or replacing the
T cells as described above, but also by using agents such as bacterial
lipopolysaccharide (LPS) or polyanions whose mode of action may obviate the
necessity for a full complement of specific T-cell helper activity. For example, it
has been shown in mice that when tolerance to HGG is being maintained at the
T-cell level only, injection of HGG and LPS terminates the tolerant state (21) .
Similarly, it has been reported that an unresponsive state to heterologous
erythrocytes can be terminated by polyanions such as dextran sulfate (22) .
Nonspecific T-cell stimulation may also bypass the requirement for specific
T-B cell interaction for the termination of tolerance. Thus, tolerance to HGG in
B6AF 1 mice, at a time when unresponsiveness was presumably maintained with
tolerant T cells, was terminated by the administration of the immunogen along
with semiallogeneic spleen cells (A strain) (23) . On the other hand, injection of
syngeneic spleen cells along with immunogen did not terminate the tolerant
state. Allogeneic cells have been shown to replace the requirement for specific
T-cell helper effect in rats even when the allogeneic cells came from a donor
tolerant to the antigen in question (24) . Presumably, the transferred parental
(semiallogeneic) or allogeneic T cells are stimulated by histocompatibility
antigens on host cells and these stimulated cells provide the helper effect
nonspecifically. Alternatively, the host B cells plus antigen may direct their
facilitation by allogeneic T cells.
Antibody in antigen-antibody complexes has been demonstrated either to
inhibit or to enhance immunological responsiveness to the complexed antigen.
Antibody-mediated suppression of specific responsiveness has been reviewed
(25), and most of the experimental evidence suggests that the suppression is due
to an afferent inhibition of the response in which antibody masks recognition of
the antigenic determinants in question (26) . On the other hand, the experiments
reported here are dependent upon an enhanced immunogenicity afforded by
antibody-antigen complexes. This may be effected through more than one
mechanism. As described here, the addition of heterologous cross-reacting
antibody to antigen increases the number of determinants capable of interacting
with T cells and thus increases the T-cell helper effect for B-cell antibody
formation. That the heterologous antibody be directed against a cross-reacting
antigen is mandated by the requirement for exposed antigenic determinants for
B-cell stimulation (27) . The use of syngeneic antibody-antigen complexes may
also result in an enhanced antibody response (G . Terres, personal communica-
tion). In this case, the mechanism must be different for there are few new
determinants to interact with T cells. Homologous complex stimulation of theG. S. HABICHT, J. M. CHILLER, AND W. O. WEIGLE
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immune response may result from the increased localization of antigen through
Fc receptors (28) or other receptors (29) on immunocompetent cells or through
increased uptake of antigen by splenic macrophages (30) .
Summary
It was possible to terminate the induced unresponsive state to bovine serum
albumin (BSA) and the natural unresponsive state to autologous thyroglobulin in
rabbits (RTg) by immunization with complexes composed of heterologous
cross-reacting antibody and the tolerated antigens. The unresponsive state was
terminated in rabbits made unresponsive by neonatal injections of BSA and then
3 mo later injected with complexes composed of BSA and guinea pig antihuman
serum albumin. This termination was manifested by the presence of anti-BSA
plaque-forming cells. Similarly, the natural unresponsive statewas terminated in
adult rabbits injected with complexes between RTg and guinea pig antibovine
thyroglobulin (BTg) in that thyroid lesions and circulating anti-RTg were
produced. The results can be best explained by the presence of unresponsive T
cells and competent B cells, where the guinea pig gamma globulin (antibody)
activates T cells specific for the guinea pig gamma globulin portion of the
complexes and thus permits stimulation of B cells competent to the exposed
determinants of the tolerated (BSA or RTg) portion of the complexes. The de-
tailed mechanism for the activation of B cells in tolerant animals is discussed.
The authors wish to acknowledge the capable technical assistance of Ms. Sandra Cossentine andthe
secretarial assistance of Ms. Linda Norwood.
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